Shares in Novo Nordisk have collapsed by nearly 20 percent after the pharmaceutical giant warned of a sharp decline in revenue for 2026.

The Danish maker of the blockbuster weight-loss drugs Wegovy and Ozempic shocked investors with a forecast predicting sales could fall by as much as 13 percent next year. The dismal outlook is driven by a perfect storm of intensifying competition from US rival Eli Lilly, patent expiries in key markets, and aggressive price-cutting measures enforced by the Trump administration in the United States.

The End of an Era?

For years, Novo Nordisk has been the undisputed king of the obesity drug market, but its crown is slipping. [...](asc_slot://start-slot-3)The company’s new CEO, Mike Doustdar, admitted that 2026 would bring "unprecedented pricing pressure." The details of the headwinds are stark:

• Price Wars: In a deal with the US government, the monthly cost of Wegovy has been slashed from over $1,000 (approx. KES 130,000) to around $350 (approx. KES 45,500).
• Generic Threats: The patent for semaglutide, the active ingredient in its flagship drugs, is expiring in markets like India, China, and Brazil, opening the floodgates for cheaper generics.
• Competitor Surge: Eli Lilly’s Zepbound is gaining rapid market share with clinical data suggesting superior weight-loss efficacy.

Market Reaction

The market’s reaction was brutal and immediate. Billions of dollars were wiped off Novo’s market value in hours, erasing gains made over the last year. Analysts described the guidance as a "reality check" for a sector that had been priced for perpetual exponential growth.

"This is a painful transition, but an investment in our future," Doustdar assured investors, though the reassurance did little to stem the sell-off. As the obesity drug wars heat up, the days of monopoly-like profits for the Danish firm appear to be over.